NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After Anti-programmed Death-ligand 1 (PD-L1) Therapy

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I/II

Latest Information Update: 17 Sep 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Avelumab (Primary) ; Bevacizumab (Primary) ; Brachyury peptide vaccine (Primary) ; Capecitabine (Primary) ; Cisplatin (Primary) ; Cyclophosphamide (Primary) ; ETBX-051 (Primary) ; ETBX-061 (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; High affinity CD-expressing natural killer cell therapy ImmunityBio (Primary) ; Nogapendekin alfa inbakicept (Primary) ; Omega-3-acid ethyl esters (Primary) ; Paclitaxel (Primary)
Indications Merkel cell carcinoma
Focus Adverse reactions; Therapeutic Use
Sponsors NantKwest

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com